Display options
Cite
Lee J, Ahn E, Kissick HT, et al. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap. 2015;6(1):7-17doi: 10.1615/ForumImmunDisTher.2015014188.
Lee, J., Ahn, E., Kissick, H. T., & Ahmed, R. (2015). Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on immunopathological diseases and therapeutics, 6(1), 7-17. https://doi.org/10.1615/ForumImmunDisTher.2015014188
Lee, Junghwa, et al. "Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway." Forum on immunopathological diseases and therapeutics vol. 6,1 (2015): 7-17. doi: https://doi.org/10.1615/ForumImmunDisTher.2015014188
Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap. 2015;6(1):7-17. doi: 10.1615/ForumImmunDisTher.2015014188. PMID: 28286692; PMCID: PMC5341794.
Copy Download .nbib Format: NLM
Share it on

For Immunopathol Dis Therap. 2015;6(1):7-17. doi: 10.1615/ForumImmunDisTher.2015014188.

Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.

Forum on immunopathological diseases and therapeutics

Junghwa Lee, Eunseon Ahn, Haydn T Kissick, Rafi Ahmed

Affiliations

  1. Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.

PMID: 28286692 PMCID: PMC5341794 DOI: 10.1615/ForumImmunDisTher.2015014188

Abstract

T-cell exhaustion due to persistent antigen stimulation is a key feature of chronic viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell exhaustion, and blocking the PD-1 pathway restores T-cell function and improves pathogen control and tumor eradication. Immunotherapy targeting the PD-1 inhibitory receptor pathway has demonstrated significant antitumor activity. Recently, antibodies blocking PD-1 have been approved for use in cancer patients. In this review, we summarize the role of the PD-1 pathway in chronic infection and cancer and the therapeutic potential of PD-1-directed immunotherapy in patients with chronic infection or cancer.

Keywords: T-cell exhaustion; cancer; chronic infection; immunotherapy; programmed cell death-1

References

  1. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
  2. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  3. Blood. 2009 Aug 20;114(8):1537-44 - PubMed
  4. Immunity. 2009 Dec 18;31(6):859-71 - PubMed
  5. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 - PubMed
  6. Cancer Gene Ther. 2012 Sep;19(9):637-43 - PubMed
  7. EMBO J. 1992 Nov;11(11):3887-95 - PubMed
  8. Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21182-7 - PubMed
  9. J Clin Invest. 2013 Jun;123(6):2604-15 - PubMed
  10. J Exp Med. 2012 Jun 4;209(6):1201-17 - PubMed
  11. J Clin Oncol. 2010 Jul 1;28(19):3167-75 - PubMed
  12. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
  13. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  14. Clin Cancer Res. 2013 Jan 15;19(2):462-8 - PubMed
  15. Nat Rev Immunol. 2015 Jan;15(1):45-56 - PubMed
  16. Nat Immunol. 2009 Jan;10(1):29-37 - PubMed
  17. Nat Immunol. 2011 Jun;12(6):492-9 - PubMed
  18. J Exp Med. 1998 Dec 21;188(12):2205-13 - PubMed
  19. Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15001-6 - PubMed
  20. J Virol. 2007 Sep;81(17):9249-58 - PubMed
  21. Clin Exp Immunol. 2013 Jun;172(3):500-6 - PubMed
  22. Nat Med. 2003 May;9(5):540-7 - PubMed
  23. Cell. 2009 Jul 10;138(1):30-50 - PubMed
  24. Clin Cancer Res. 2009 Mar 1;15(5):1623-34 - PubMed
  25. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  26. J Clin Oncol. 2015 May 1;33(13):1430-7 - PubMed
  27. Clin Cancer Res. 2013 Mar 1;19(5):1021-34 - PubMed
  28. Nat Med. 2006 Nov;12(11):1301-9 - PubMed
  29. J Clin Invest. 2010 Jul;120(7):2508-15 - PubMed
  30. J Exp Med. 2010 Sep 27;207 (10 ):2187-94 - PubMed
  31. Nat Med. 2003 May;9(5):562-7 - PubMed
  32. FEBS Lett. 2004 Sep 10;574(1-3):37-41 - PubMed
  33. J Virol. 2006 Nov;80(22):11398-403 - PubMed
  34. Cancer Med. 2013 Oct;2(5):662-73 - PubMed
  35. PLoS One. 2013 May 22;8(5):e63818 - PubMed
  36. Nature. 2009 Mar 12;458(7235):206-10 - PubMed
  37. Nature. 2006 Feb 9;439(7077):682-7 - PubMed
  38. N Engl J Med. 2013 Jul 11;369(2):134-44 - PubMed
  39. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  40. J Clin Invest. 2011 Jun;121(6):2350-60 - PubMed
  41. Curr Opin Immunol. 2007 Aug;19(4):408-15 - PubMed
  42. Nat Immunol. 2001 Mar;2(3):261-8 - PubMed
  43. J Exp Med. 2000 Oct 2;192(7):1027-34 - PubMed
  44. Sci Transl Med. 2013 Aug 28;5(200):200ra116 - PubMed
  45. Nature. 2006 Sep 21;443(7109):350-4 - PubMed
  46. J Virol. 2005 Jul;79(14):8960-8 - PubMed
  47. J Clin Oncol. 2014 Apr 1;32(10):1020-30 - PubMed
  48. Annu Rev Immunol. 2008;26:677-704 - PubMed
  49. Immunity. 2007 Oct;27(4):670-84 - PubMed
  50. Cancer Res. 2012 Oct 15;72(20):5209-18 - PubMed
  51. J Exp Med. 1998 May 4;187(9):1383-93 - PubMed
  52. J Clin Oncol. 2013 Dec 1;31(34):4311-8 - PubMed
  53. Nat Med. 2006 Oct;12(10):1198-202 - PubMed
  54. J Immunol. 2011 Mar 1;186(5):2772-9 - PubMed
  55. Cancer Res. 2004 Apr 15;64(8):2865-73 - PubMed
  56. Nature. 2014 Nov 27;515(7528):558-62 - PubMed
  57. Cancer Res. 2005 Feb 1;65(3):1089-96 - PubMed
  58. Nat Med. 1999 Dec;5(12):1365-9 - PubMed
  59. Cancer Res. 2012 Feb 15;72(4):917-27 - PubMed
  60. J Immunol. 2008 Nov 15;181(10):6738-46 - PubMed
  61. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8 - PubMed
  62. J Immunol. 2013 Jan 1;190(1):211-9 - PubMed
  63. J Immunol. 2004 Jul 15;173(2):945-54 - PubMed
  64. Nat Med. 2002 Aug;8(8):793-800 - PubMed
  65. Nat Rev Drug Discov. 2014 May;13(5):379-95 - PubMed
  66. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20428-33 - PubMed
  67. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 - PubMed
  68. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016-21 - PubMed
  69. J Exp Med. 2008 Mar 17;205(3):543-55 - PubMed
  70. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  71. J Exp Med. 2001 Apr 2;193(7):839-46 - PubMed

Publication Types

Grant support